Recombinant influenza B virus HA and NA antigens administered in equivalent amounts are immunogenically equivalent and induce equivalent homotypic and broader heterovariant protection in mice than conventional and live influenza vaccines

Human Vaccines

Volumn 4, Issue 6, 2008, Pages 420-424

  Johansson, Bert E ^a   Brett, Ian C ^b  

^a Innovation Sciences   (United States)

^b STONY BROOK UNIVERSITY   (United States)

Author keywords

B influenza; Hemagglutinin; Heterotypic; Immunization; Influenza; Neuraminidase; Vaccine

Indexed keywords

INACTIVATED VACCINE; INFLUENZA VACCINE; INFLUENZA VIRUS HEMAGGLUTININ; LIVE VACCINE; RECOMBINANT VACCINE; VIRUS SIALIDASE; HEMAGGLUTININ HA1, INFLUENZA B VIRUS; NA GLYCOPROTEIN, INFLUENZA B VIRUS; VIRUS ANTIBODY; VIRUS PROTEIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY TITER; ARTICLE; BAGG ALBINO MOUSE; CONTROLLED STUDY; DRUG EFFICACY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HEMAGGLUTINATION INHIBITION TEST; IMMUNE RESPONSE; IMMUNOGENICITY; INFLUENZA; INFLUENZA VACCINATION; INFLUENZA VIRUS B; MOUSE; NONHUMAN; SEROLOGY; VACCINE PRODUCTION; VIRUS HEMAGGLUTINATION; VIRUS REPLICATION; VIRUS STRAIN; ANIMAL; BACULOVIRUS; BLOOD; COMPARATIVE STUDY; GENETICS; IMMUNOLOGY; LUNG; VIROLOGY;

ANIMALS; ANTIBODIES, VIRAL; BACULOVIRIDAE; FEMALE; HEMAGGLUTININ GLYCOPROTEINS, INFLUENZA VIRUS; INFLUENZA B VIRUS; INFLUENZA VACCINES; LUNG; MICE; MICE, INBRED BALB C; VACCINES, ATTENUATED; VACCINES, INACTIVATED; VACCINES, SYNTHETIC; VIRAL PROTEINS;

EID: 56149123794     PISSN: 15548600     EISSN: 15548619     Source Type: Journal    
DOI: 10.4161/hv.4.6.6201     Document Type: Article

References (40)

1. Yusuf K, Soraisham AS and Fonseca K. Fatal influenza B virus pneumonia in a preterm neonate: case report and review of the literature Journal of Perinatology 2007; 27:623-5.
2. Kilbourne ED. Influenza. Plenum Publishing, New York 1987; 164-5.
3. Couch RB. Advances in influenza virus vaccine research. Ann N Y Acad Sci 1993; 685:803-12.
4. Barker W, Mullooly J. Influenza vaccination of elderly persons. J Am Med Assoc 1980; 244:2547.
5. Davenport F, Hennessy A, Brandon F, Webster R, et al. Comparisons of serologic and febrile responses in humans to vaccination with influenza A viruses or their hemagglutinins. J Lab Clin Med 1964; 63:5.
6. Belshe RB. A review of attenuation of influenza viruses by genetic manipulation. Am J Respir Crit Care Med 1995; 152:72-5.
7. Brett IC, Johansson BE. Immunization against influenza A virus: Comparison of conventional inactivated, live-attenuated and recombinant baculovirus produced purified hemagglutinin and neuraminidase vaccines in a murine model system Virology 2005; 339:273-80.
8. Johansson B, Matthews J, Kilbourne E. Supplementation of conventional influenza A vaccine with purified viral neuraminidase results in a balanced and broadened immune response. Vaccine 1998; 16:1009-15.
9. Johansson B. Immunization with influenza A virus hemagglutinin and neuraminidase produced in baculovirus results in a balanced and broadened immune response superior to conventional vaccine. Vaccine 1999; 17:2073-80.
10. Gross P, Ennis F, Gaerlan L, Denson L, Denning C, Schiffman D. A controlled doubleblind comparison of the reactogenicity, immunogenicity, and protective efficacy of whole-virus and split-product influenza vaccines in children. J Infect Dis 1977; 136:623.
11. Kilbourne E. Influenza: viral determinants of the pathogenicity and epidemicity of an invariant disease of variable occurrence. Philos Trans R Soc London Biol 1980; 288:291.
12. Kilbourne E, Grajower B, Johansson B. Independent and disparate evolution in nature of influenza A virus hemagglutinin and neuraminidase. Proc Natl Acad Sci USA 1990; 87:786-90.
13. Chen Z, Matsuo K, Asanuma H, Takahashi H, Iwasaki T, Suzuki Y, Aizawa C, Kurata T, Tamura S. Enhanced protection against a lethal influenza virus challenge by immunization with both hemagglutinin- and neuraminidase-expressing DNAs. Vaccine 1999; 7:653-9.
14. Chen Z, Kadowaki S, Hagiwara Y, Yoshikawa T, Sata T, Kurata T, Tamura S. Protection against influenza B virus infection by immunization with DNA vaccines. Vaccine 2001; 19:1446-55.
15. Couch R, Douglas R, Fedson D, Kasel J. Correlated studies of a recombinant influenza virus vaccine. III. Protection against experimental influenza in man. J Infect Dis 1971; 124:473.
16. Couch R, Kasel J, Gerin J, Schulman J, Kilbourne E. Induction of partial immunity to influenza by a neuraminidase-specific influenza A virus vaccine in humans. J Infect Dis 1974; 129:411.
17. Johansson B, Bucher D, Kilbourne E. Purified influenza virus hemagglutinin and neuraminidase are equivalent in stimulation of antibody response but induce contrasting types of immunity to infection. J Virol 1989; 63:1239.
18. Johansson B, Tiso V, Pokorny B. Supplementation of conventional trivalent influenza vaccine with purified viral N1 and N2 neuraminidases induces a balanced immune response without antigenic competition. Vaccine 2002; 20:1670-4.
19. CDC Update: Influenza Activity-United States, September 30, 2007-February 9, 2008. Morb Mortal Wkly Rep 57:1-5.
20. Johansson B, Moran T, Bona C, Popple S, Kilbourne E. Immunologic response to influenza virus neuraminidase is influenced by prior experience with the associated viral hemagglutinin: II. Sequential infection of mice simulates human experience. J Immunol 1987a; 139:2010.
21. Johansson B, Moran T, Kilbourne E. Antigen-presenting B cells and helper T cells cooperatively mediate intravirionic antigenic competition between influenza A virus surface glycoproteins. Proc Natl Acad Sci USA 1987b; 84:6869.
22. Johansson B, Moran T, Bona C, Kilbourne E. Immunologic response to influenza virus neuraminidase is influenced by prior experience with the associated viral hemagglutinin: III. Reduced generation of neuraminidase-specific helper T cells in hemagglutinin-primed mice. J Immunol 1987c; 139:2015.
23. Johansson B, Kilbourne E. Dissociation of influenza virus hemagglutinin and neuraminidase eliminates their intravirionic antigenic competition. J Virol 1993; 67:5721.
24. Johansson BE, Kilbourne ED. Immunization with dissociated neuraminidase, matrix, and nucleoproteins from influenza A virus eliminates cognate help and antigenic competition. Virology 1996; 225:136-44.
25. Johansson BE, Kilbourne ED. Comparative long-term effects in a mouse model system of influenza whole virus vaccine and purified neuraminidase vaccine followed by sequential infections. J Inf Dis 1991; 162:800-8.
26. Supplement: World Congress on Vaccines and Immunology. Vaccine 2007; 25:3062-5.
27. Hervas-Stubbs S, Rueda P, Lopez L and Leclerc C. Insect baculoviruses strongly potentiate adaptive immune responses by inducing type I IFN. J Immunology 2007; 178:2361-9.
28. Kilbourne E, Couch R, Kasel J, Keitel J, Cate T, Quarles J, Grajower B, Pokorny B, Johansson B. Purified influenza A virus N2 neuraminidase vaccine is immunogenic and non-toxic in humans. Vaccine 1995; 13:1799.
29. Kilbourne ED. Influenza Pandemics: Can We Prepare for the Unpredictable? Viral Immunology 2004; 17:350-7.
30. Archetti J, Horsfall F. Persistent antigenic variation of influenza A virus after incomplete neutralization in ovo with heterologous immune serum. J Exp Med 1950; 92:1521.
31. CDC Update: Influenza Activity - United States, 2003-2004 season. Morb Mortal Wkly Rep 53:284-7.
32. Hossain MJ, Mori I, Dong L, Kimora Y. Egg adapted replication restricted virus protects mice against lethal influenza. Vaccine 2000; 18:3082-90.
33. Bromage ES and Kaattaria SL. Simultaneous quantitative analysis of multiple protein species within a single sample using standard scanning densitometry. Journal of Immunological Methods 2007; 323:109-13.
34. Johansson B, Price P, Kilbourne E. Immunogenicity of influenza A virus N2 neuraminidase produced in insect larvae by baculovirus recombinants. Vaccine 1995; 9:841.
35. Price P, Reichelderfer C, Johansson B, Kilbourne E, Acs G. Complementation of recombinant baculovirus by coinfection with wild-type virus facilitates production in insect larvae of antigenic proteins of hepatitis B virus and influenza virus. Proc Natl Acad Sci USA 1989; 86:1453.
36. Hocart M, Grajower B, Donabedian A, Pokorny B, Whitaker C, Kilbourne E. Preparation and characterization of a purified influenza virus neuraminidase vaccine. Vaccine 1995; 13:584-1793.
37. Lowry OH, Rosebrough NJ, Farr AC, Radall RI. Protein measurement with the folinphenol reagent. J Biol Chem 1951; 193:265.
38. Kilbourne ED, Pokorny BA, Johansson B, Brett I, Milev Y, Matthews JT. Protection of mice with recombinant influenza virus neuraminidase. J Inf Dis 2004; 189:459-61.
39. Powers D, Kilbourne E, Johansson B. Neuraminidase-specific antibody responses to inactivated influenza vaccine in young and elderly adults. Clin Diagn Lab Immunol 1996; 3:511.
40. Sever J. Application of a microtechnique to viral serological investigations. J Immunol 1962; 88:320-3.